Latest news updates... Oct 26
Latest Pharma Update... Aug 23
Immutep was granted Fast Track designation for efti to treat 1st line HNSCC patients by the US FDA in early April 2021. ... Jul 12
Another pharma collaboration for the advancement of cancer therapies ... Mar 22
... Dec 18
Patients with newly diagnosed esophageal and GEJ cancer face an aggressive disease with a poor prognosis, despite the currently available treatment options... Dec 17
... Dec 16
... Dec 11
I-Mab's global collaboration with AbbVie will facilitate global development of lemzoparlimab... Dec 05
LENVIMA plus everolimus were evaluated versus sunitinib for the first-line treatment of patients with advanced renal cell carcinoma... Nov 10
Median OS of 13.3 months has been observed in the Phase I/IIa study for patients treated with Bria-IMTâ„¢ in combination with immune ... Oct 21
NKMax America has developed a proprietary NK cell expansion and activation technology platform which allows it to produce unprecedented commercial amounts of autologous and allogeneic ... Oct 20
FDA approves expanded indication for Merck’s KEYTRUDA (pembrolizumab) in adult patients with relapsed or refractory classical hodgkin lymphoma (cHL) ... Oct 16
... Oct 15
PharmAbcine is a clinical-stage biotech company developing fully human therapeutic antibodies to treat cancer and neovascular disease... Sep 22
Keytruda would be soon launched in Japan for the treatment of cancerous tumors... Aug 27
PharmAbcine signs long-term contract manufacturing organization agreement for Olinvacimab with Binex ... Jun 27
The experimental antibody has neutralized the virus in cell cultures. While that's early in the drug development process, the antibody may help prevent or ... May 05
Novartis,Allergan and Merck joins the list after Pfizer,increases drug prices in US... Jan 07
-Advertisements-
Wednesday, May 15, 2024
.jpeg)
